Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agenus (AGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Area51 who wrote (30)	7/20/2005 9:21:01 AM
From: The Dodgy Ticker	Read Replies (1) \| Respond to of 146

I'm hoping that since the results of the phIII trial for RCC keep getting pushed back (because there haven't been the required number of "events"), the implication is that the treatment with Oncophage is working.

To: Area51 who wrote (30)	12/16/2015 1:02:34 PM
From: Kirk ©	Respond to of 146

Are you still posting here on SI? Nice jump today on this news: Jefferies Starts Agenus Inc. (AGEN) at Buy; Sees 100% Upside December 16, 2015 7:54 AM EST Jefferies initiates coverage on Agenus Inc. (NASDAQ: AGEN) with a Buy rating and a price target of $8.00. Analyst Biren Amin commented, "Agenus is developing a comprehensive Immuno-Oncology (IO) platform consisting of multiple checkpoints both fully owned and through partnerships and could be a leader in cancer vaccine development through the deployment of its QS-21 adjuvant which could increase the efficacy of cancer vaccines. AGEN is also partnered with Merck and Incyte across 9 novel IO programs totaling >$450M in milestones. Therefore, AGEN's $130M EV offers significant upside, in our view."

To: Area51 who wrote (30)	1/29/2019 9:39:52 AM
From: Kirk ©	Respond to of 146

Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare - The Biotech Electronic Security Token (BEST) is designed to be an innovative and transformative way to finance drug development through increasing liquidity, minimizing dilution, and improving capital allocation - BEST democratizes financing through targeted investments for specific therapeutic drug products LEXINGTON, Mass., Jan. 29, 2019 / PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today, the upcoming launch of its Biotech Electronic Security Token (BEST), the first digital security offering in healthcare. Tokenization will enable qualified investors to directly invest in a single biotech product while preserving shareholder equity. The growing adoption of blockchain technology, together with the latest financial regulatory changes, offers new alternatives to fund selected products with digital securities and opens an unprecedented opportunity to target financial investments in pharmaceutical product development. "Today, by announcing the first of its kind asset backed digital security offering in healthcare, we open the doors for a transformative financing vehicle," said Garo Armen, Chairman and CEO of Agenus. "We believe this unique structure will pave the way for allowing targeted investment by qualified investors in the development of therapeutic products. This instrument, powered by blockchain technology, enables us to revolutionize the financing of drug development." Each token to be issued will represent a portion of potential future US sales of AGEN2034, Agenus' anti-PD-1 antibody, now in pivotal clinical trials, and is entitled to a defined return claimable through token-by-token redemption starting with the first US commercial sale of AGEN2034. Qualified investors will be eligible to purchase BEST securities under preferred terms in the initial stage of the Digital Security Offering. Investments into this unique financing mechanism of up to $100M will accelerate the development, commercialization, distribution, and indication expansion for anti-PD-1, AGEN2034. This type of innovation directly links Agenus' mission of speeding the development of immuno-oncology therapies, advancing more combination trials, and expanding its reach to additional indications. The company's recently announced collaboration with Gilead provides $150M in up-front cash and approximately $1.7 Billion in future fees and milestones to fund activities. Introducing BEST expands its product specific financing options for drug development while providing investors with an attractive risk-return profile. Agenus anticipates the industry will adopt this financing model as an attractive means of obtaining capital in coming years. BEST is expected to lead the emergence of a new marketplace for asset-specific securities providing investors with unique funding alternatives and options for managing risk. Agenus expects to open investment in BEST to qualified investors in mid-February. Terms and conditions of the offering will be described in the company's offering documents at that time. Investor validation and participation will be managed through Atomic Capital's Platform. *The announcement will be made today, in a presentation by Dr. Garo Armen at the Atomic Capital Event: Digital Assets for Professional Investors in New York, NY.* About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter About BEST Biotech Electronic Security Tokens (BEST) are blockchain based securities that will be issued in accordance with Regulation D of the Securities Act of 1933, which will entitle the holder to a defined multiple of the original purchase price upon redemption, that may be claimed starting with the first US commercial sale of the underlying asset. BEST holders will benefit from downside protection provisions including a capital recall feature allowing them to reclaim a substantial portion of the original purchase price at any time following initial investment while retaining a stake in the security's upside that would result in a "make whole" outcome if the underlying project is successful. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated terms, timing, size and impact of Agenus' potential BEST offering, the potential approval and commercialization of AGEN2034. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact: Jennifer Buell, PhD Agenus Inc. 781-674-4420 Jennifer.Buell@agenusbio.com 1Through AgenTus Therapeutics, a subsidiary of Agenus SOURCE Agenus Inc. To view this release online and get more information about Agenus Bio InvestorRoom visit: investor.agenusbio.com

To: Area51 who wrote (30)	7/6/2019 12:56:50 PM
From: Kirk ©	Respond to of 146

Please change the title to the new name, Agenus. agenusbio.com Thanks

To: Area51 who wrote (30)	7/11/2019 1:44:57 PM
From: Kirk ©	Read Replies (1) \| Respond to of 146

What to Know About Shingles and Its Vaccine How to prevent this painful condition and the right treatments if you do get it By Catherine Roberts July 10, 2019 consumerreports.org

To: Area51 who wrote (30)	3/10/2020 1:01:37 PM
From: Kirk ©	Respond to of 146

It is great to see good news move the stock! First QS-21 Royalty Payment Due to Agenus is Triggered $15.1M Milestone from HealthCare Royalty Partners LEXINGTON, Mass., March 10, 2020 / PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced the triggering of a $15.1M milestone payment from HealthCare Royalty Partners (HCR) based on net sales of GlaxoSmithKline's (GSK's) Shingrix vaccine exceeding $2.0B in 2019. Agenus' proprietary QS-21 Stimulon™ is one of the most potent adjuvants known and is a key component in GSK's Shingrix vaccine, which has generated blockbuster sales exceeding $2.3Bn in its second year after launch. Agenus is due another milestone amounting to $25.5M if Shingrix net sales exceed $2.75B over four consecutive quarters before 2026. About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated additional milestone payment of $25 million based on GSK's sales of Shingrix. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact: Agenus Inc. Regina Grebla, PhD 781-674-4495 Regina.Grebla@agenusbio.com SOURCE Agenus Inc. News Release Issued: Mar 10, 2020 (9:14am EDT) To view this release online and get more information about Agenus Bio InvestorRoom visit: investor.agenusbio.com

To: Area51 who wrote (30)	6/17/2021 9:32:23 AM
From: Kirk ©	Respond to of 146

Agenus Gets FDA Priority Review of Balstilimab in Cervical Cancer DJ REALTIME NEWS – 9:01 AM ET 06/17/2021 Agenus Inc. ( AGEN ) on Thursday said the U.S. Food and Drug Administration granted priority review to its biologics license application for balstilimab for the treatment of recurrent or metastatic cervical cancer. The Lexington, Mass., clinical-stage immuno-oncology company said the agency set a target action date of Dec. 16 for the application, which covers balstilimab in cervical cancer with disease progression on or after chemotherapy